[Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause].
The effect of adjuvant treatment with tamoxifen on recurrence and survival rates was determined in a prospective randomized trial in 98 postmenopausal women (mean age 62.7 [49-77] years) with lymph node-negative breast cancer who had undergone modified radical mastectomy with axillary lymphadenectomy. The tamoxifen group (n = 48) received 10 mg of the drug twice daily for one year. After a mean period of 8 (6-11) years the tamoxifen group had a significantly higher rate of survival without recurrence than the control (no tamoxifen) group (83% vs 61.5%, P = 0.02) and a higher overall survival rate (95% vs 81.9%, P = 0.05). These results indicate that adjuvant tamoxifen favourably influences the prognosis for postmenopausal women with lymph node-negative breast cancer after radical mastectomy with axillary lymphadenectomy.
Kurz
C
C
1. Universitäts-Frauenklinik, Klinische Abteilung für Onkologie, Universität Wien.
Scholten
C
C
Zielinski
C
C
Czerwenka
K
K
Kubista
E
E
Spona
J
J
Sevelda
P
P
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011446:Prospective Studies; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen
Adjuvante Hormontherapie bei lymphknoten-negativen Mammakarzinompatientinnen in der Postmenopause.